Global Neurotrophic Keratitis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Neurotrophic keratitis treatment market Segmentation, By Treatment Type (Antibiotic Eye Drops, Artificial Tears, Amniotic Membrane Transplantation, Surgical Treatment, Recombinant Human Nerve Growth Factor (Cenegermin), and Others), Disease Stages (Stage I, Stage II, and Stage III), End User (Hospitals, Ophthalmology Clinics, Research & Academic Institutes, and Ambulatory Surgical Centers)- Industry Trends and Forecast to 2032

Neurotrophic keratitis treatment market Size

• The global neurotrophic keratitis treatment market size was valued at USD 187 million in 2024 and is expected to reach USD 391.61million by 2032, at a CAGR of 9.68% during the forecast period
• This growth is driven by factors such as the increasing prevalence of neurotrophic keratitis, rising adoption of novel therapies like cenegermin (Oxervate), and growing awareness among healthcare professionals regarding early diagnosis and intervention

Neurotrophic keratitis treatment market Analysis

• Neurotrophic keratitis (NK) is a rare degenerative corneal disease caused by damage to the trigeminal nerve, resulting in decreased corneal sensitivity and impaired healing. Treatment aims to restore corneal integrity, prevent ulceration, and preserve vision, using pharmacological and surgical interventions
• The demand for neurotrophic keratitis treatment is fueled by improved diagnosis rates, regulatory approvals of novel biologics like cenegermin, and expanded reimbursement frameworks in developed countries
• North America is expected to dominate the  Neurotrophic keratitis treatment market with a share of 36.4%, attributed to the availability of FDA-approved therapies, high healthcare expenditure, and the strong presence of leading ophthalmic companies
• Asia-Pacific is expected to be the fastest growing region in the  Neurotrophic keratitis treatment market during the forecast period due to increasing awareness, growing access to eye care, and rising incidence of diabetes and herpes infections, both of which are risk factors for NK.
• The recombinant human nerve growth factor (cenegermin) segment is expected to lead the market with a market share of 41.3% due to its proven efficacy in promoting corneal healing and the fact that it is the only FDA-approved drug specifically indicated for neurotrophic keratitis. Its targeted mechanism of action and increasing global adoption following regulatory approvals in multiple regions contribute to its dominant market position

Report Scope and  Neurotrophic Keratitis Treatment Market Segmentation 

Neurotrophic keratitis treatment market Trends

“Increasing Diagnosis and Availability of Targeted Therapies”

• One prominent trend in the neurotrophic keratitis treatment market is the increasing rate of diagnosis coupled with the launch of targeted biologics such as cenegermin (Oxervate).
• As clinical awareness grows among ophthalmologists, especially regarding early-stage neurotrophic keratitis, more patients are being diagnosed before reaching advanced corneal damage 

  • For instance, novel treatments such as Oxervate by Dompé Pharma have demonstrated strong efficacy in restoring corneal integrity, providing a much-needed solution for a previously underserved patient population.

• This trend is significantly transforming NK management, enabling earlier intervention, reducing the need for surgical treatment, and improving patient outcomes
• The neurotrophic keratitis treatment market is expected to witness sustained growth, supported by increased diagnostic capabilities, ongoing innovation in regenerative ophthalmology, and a focus on improving quality of life for patients with rare ocular diseases

Neurotrophic keratitis treatment market Dynamics

Driver

“Growing Need Due to Rising Prevalence and Awareness of Rare Diseases”

• The increasing recognition and diagnosis of Neurotrophic Keratitis (NK)—a rare degenerative corneal disease often associated with nerve damage—are significantly contributing to the growing demand for effective pharmacological and regenerative treatments.
• As awareness of rare and orphan eye diseases improves globally, more patients are being correctly diagnosed, which drives the demand for specialized therapies, including recombinant human nerve growth factor (rhNGF), autologous serum eye drops, and novel ophthalmic formulations
• The growing prevalence of associated conditions, such as herpes simplex virus, diabetes mellitus, and post-surgical corneal nerve injuries, further elevates the need for targeted treatments.
• Ongoing advances in ocular regenerative medicine and precision therapy highlight the necessity for disease-specific drug development, improving corneal healing and visual outcomes
•  With a greater number of patients seeking medical intervention and access to treatment programs, the demand for Neurotrophic Keratitis therapies continues to rise, supporting long-term market growth.

For instance,

• In August 2023, according to a study published by the National Eye Institute (NEI), increased awareness initiatives and better training for ophthalmologists led to a surge in NK diagnosis rates, which had historically been underrecognized due to nonspecific early symptoms.
• In March 2022, an article published in the Orphanet Journal of Rare Diseases reported that global rare disease tracking initiatives identified rising incidences of neurotrophic keratitis linked to systemic comorbidities and surgical procedures, boosting demand for rhNGF-based therapies. 
• As a result of rising disease prevalence and global rare disease advocacy, there is a substantial increase in demand for innovative therapies in the Neurotrophic Keratitis treatment market.

Opportunity

“Breakthroughs in Targeted Therapies and Orphan Drug Designations”

• The development of targeted therapies, including rhNGF formulations and regenerative eye drops, presents significant opportunities in the Neurotrophic Keratitis treatment market.
• Orphan drug designations and regulatory incentives such as priority review, market exclusivity, and research grants are encouraging pharmaceutical firms to invest in R&D for this underserved condition.
•  Targeted treatments such as cenegermin (Oxervate) and novel candidates in clinical development show promising results in promoting corneal nerve regeneration and epithelial healing.

For instance,

• In January 2025, a clinical update published in The Ocular Surface highlighted that rhNGF therapies significantly improved corneal sensitivity and epithelial integrity in moderate to severe NK cases, supporting their use as first-line therapies.
• In October 2023, the U.S. FDA granted Orphan Drug Designation to an investigational topical neurotrophic compound by a European biotech company, accelerating clinical trials and increasing investor attention. 
• The regulatory and scientific momentum surrounding novel ophthalmic therapeutics, backed by orphan drug policies, positions the Neurotrophic Keratitis treatment market for substantial growth in the coming years.

Restraint/Challenge

“High Treatment Costs Limiting Accessibility”

• The high cost of Neurotrophic Keratitis treatments, particularly biologic-based eye drops like cenegermin, poses a significant challenge, limiting accessibility for many patients worldwide, especially in developing countries
•  These treatments, which are often essential for managing moderate to severe NK, can cost tens of thousands of dollars per treatment cycle, creating financial burdens for patients and healthcare systems
• Limited reimbursement support and restricted insurance coverage for orphan ophthalmic therapies in various regions further widen the accessibility gap

For instance,

• In November 2024, an article by The Lancet Global Health reported that the high cost of rhNGF-based therapy like Oxervate could exceed USD 90,000 per treatment course, posing challenges for broader adoption despite its proven clinical effectiveness.
• In May 2023, a review published in Rare Disease Reports highlighted the affordability barriers faced by NK patients in low- and middle-income countries due to limited regulatory frameworks supporting orphan drug reimbursement. 
• These economic constraints contribute to inequities in treatment access and outcomes, ultimately hindering the broader adoption of innovative NK therapies and limiting overall market expansion

Neurotrophic keratitis treatment market Scope

The market is segmented on the basis of type, biopsy techniques, end user, and usage.

In 2025, the recombinant human nerve growth factor (cenegermin) segment is projected to dominate the market with the largest share in the treatment type segment

The recombinant human nerve growth factor (cenegermin) segment is expected to dominate the Global Neurotrophic Keratitis Treatment Market with the largest share of 44.15% in 2025 due to its targeted therapeutic action, regulatory approvals, and growing physician adoption. Cenegermin, being the first FDA-approved biologic therapy specifically indicated for neurotrophic keratitis, offers a disease-modifying treatment option rather than symptomatic relief. Its ability to promote corneal healing and restore corneal integrity, combined with increasing awareness and reimbursement support, continues to support its leading position in the treatment landscape.

The Stage II segment is expected to account for the largest share during the forecast period in the disease stage segment

In 2025, the Stage II segment is expected to dominate the market due to the increasing diagnosis rate at this intermediate stage, where patients present with persistent epithelial defects but without severe ulceration. Timely intervention at Stage II offers a better therapeutic window for effective management and improved outcomes. The availability of innovative treatments like cenegermin, combined with enhanced screening and clinical recognition of neurotrophic keratitis in ophthalmic settings, is driving growth in this segment

Neurotrophic keratitis treatment market Regional Analysis

“North America Holds the Largest Share in the  Neurotrophic Keratitis Treatment Market”

• North America dominates the  Neurotrophic keratitis treatment market with a share of 36.4%, driven by advanced healthcare infrastructure, the high adoption of cutting-edge localization technologies, and the strong presence of key market players
• U.S. holds a significant share of 78.3% due to significant demand for advanced localization systems, such as magnetic seed and radar localization methods, driven by the high prevalence of breast cancer and the need for precise diagnostic and surgical tools
• The presence of leading companies such as Endomag, Hologic, and Merit Medical, alongside continuous advancements in breast cancer treatment technologies, continues to drive innovation in  Neurotrophic Keratitis Treatment  localization. Moreover, a high level of healthcare investment in research and development (R&D) ensures continuous improvements in localization techniques, bolstering the market's expansion
• The growing number of breast cancer surgeries and procedures in North America, along with increased patient awareness and a shift toward minimally invasive procedures, supports the market's growth. As healthcare standards improve, the demand for precise  will continue to rise, solidifying North America’s dominant position in the market

“Asia-Pacific is Projected to Register the Highest CAGR in the  Neurotrophic keratitis treatment market”

• The Asia-Pacific region is expected to witness the highest growth rate in the  Neurotrophic keratitis treatment market, driven by rapid expansion in healthcare infrastructure, increasing awareness about breast cancer, and growing procedure volumes
• Countries such as China, India, and Japan are emerging as key markets for  Neurotrophic Keratitis Treatment  localization technologies due to the rising prevalence of breast cancer and the growing demand for advanced localization techniques. Increasing awareness and early detection initiatives are fueling the adoption of non-invasive, high-precision localization tools in these regions
• Japan, with its highly advanced medical infrastructure, remains a critical market for  Neurotrophic Keratitis Treatment  localization technologies. The country continues to lead in the adoption of cutting-edge imaging systems and localization methods, enhancing the accuracy and efficiency of breast cancer treatments
• The growing focus on healthcare expansion and breast cancer treatment is poised to drive the demand for advanced localization technologies, making the APAC region the fastest-growing market for these methods

Neurotrophic keratitis treatment market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Smith+Nephew (U.K.)
• Boston Scientific Corporation (U.S.)
• Organogenesis Inc. (U.S.)
• Arthrex, Inc. (U.S.)
• Orthofix Medical Inc. (U.S.)
• Kubtec X-Ray (U.S.)
• Miltenyi Biotec GMBH (Germany)
• Naviscan (U.S.)
• PerkinElmer Inc. (U.S.)
• Thermo Fisher Scientific, Inc. (U.S.)
• Allergan (AbbVie Inc.) (U.S.)
• Bausch Health Companies Inc. (Canada)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Santen Pharmaceutical Co., Ltd. (Japan)
• Kala Pharmaceuticals, Inc. (U.S.)
• Johnson & Johnson (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Akorn, Inc. (U.S.)
• Eyevance Pharmaceuticals (U.S.)
• Alcon Inc. (Switzerland)
• Pfizer Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• F. Hoffmann-La Roche Ltd (Switzerland)

SKU-46434